A.R.T. Advisors’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

A.R.T. Advisors’s Portfolio OMED Stock Details OMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-10,429	Closed	-$24K	–	1930
2018 Q2	$24K	Buy	+10,429	New	+$30.4K	﹤0.01%	1358
2018 Q1	–	Sell	-27,052	Closed	-$110K	–	1955
2017 Q4	$110K	Buy	+27,052	New	+$118K	﹤0.01%	1241
2017 Q3	–	Sell	-59,360	Closed	-$197K	–	1924
2017 Q2	$197K	Buy	59,360 +46,624	+366%	+$193K	0.01%	1168
2017 Q1	$117K	Buy	+12,736	New	+$112K	0.01%	1249
2016 Q2	–	Sell	-82,313	Closed	-$832K	–	1880
2016 Q1	$832K	Buy	+82,313	New	+$966K	0.04%	661

Other funds holding OMED

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

A.R.T. Advisors's OMED Position: Q3 2018 in Review

A.R.T. Advisors sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q3 2018, closing a stake of 10,429 shares — an estimated $24K sold.

A.R.T. Advisors first reported a position in OMED in Q1 2016 and held it in 5 quarters. The position peaked at $832K in Q1 2016. 54 funds tracked by Wall St. Rank hold OMED as of Q3 2018.

A.R.T. Advisors reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q3 2018 after selling out during the quarter.
A.R.T. Advisors sold 10,429 OncoMed Pharmaceuticals, Inc. shares in Q3 2018, an estimated $24K.
A.R.T. Advisors first reported a position in OncoMed Pharmaceuticals, Inc. in Q1 2016 and held it in 5 quarters.
A.R.T. Advisors's OncoMed Pharmaceuticals, Inc. position peaked at $832K in Q1 2016.
54 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q3 2018.

Based on A.R.T. Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.